Drug Profile
Research programme: histamine H3 receptor antagonists - Eli Lilly and Company
Alternative Names: THBAZ; TISQLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class
- Mechanism of Action Histamine H3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Schizophrenia in USA
- 14 Nov 2005 Preclinical trials in Schizophrenia in USA (unspecified route)